Brought to you by 
Biogen gets ex-Asian rights to Mitsubishi Tanabe's Phase III-ready IBD candidate MT1303; Biogen halts development
01 Feb 2023
Executive Summary
Mitsubishi Tanabe Pharma Corp. licensed Biogen Inc. exclusive global rights (excluding Asia) to its MT1303, which is in Phase II for multiple sclerosis and Crohn’s disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biogen gets ex-Asian rights to Mitsubishi Tanabe's Phase III-ready IBD candidate MT1303; Biogen halts development
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice